Brooks Laboratories shines on acquiring 44.33% stake in SteriBrooks Penems

18 Sep 2020 Evaluate

Brooks Laboratories is currently trading at Rs. 49.15, up by 2.30 points or 4.91% from its previous closing of Rs. 46.85 on the BSE.

The scrip opened at Rs. 49.15 and has touched a high and low of Rs. 49.15 and Rs. 49.15 respectively. So far 988 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 49.15 on 18-Sep-2020 and a 52 week low of Rs. 14.05 on 30-Mar-2020.

Last one week high and low of the scrip stood at Rs. 49.15 and Rs. 38.80 respectively. The current market cap of the company is Rs. 121.41 crore.

The promoters holding in the company stood at 66.41% and Non-Institutions held 33.58 %.

Brooks Laboratories has subscribed to 7963 equity shares at the face value of Rs 10 each of SteriBrooks Penems, amounting to 44.33% of the post issue paid-up shares capital of SteriBrooks. The object of the said acquisition is to build a robust carbapenem business with integrated manufacturing capabilities. 

Brooks Laboratories has wide range of products catering to critical care segment in Parental Section like Beta Lactam, Cephalosporin & General dry powder Injectables, Ampoules and Liquid vials.

Brooks Laboratories Share Price

165.50 3.20 (1.97%)
20-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.50
Dr. Reddys Lab 1342.45
Cipla 1472.45
Lupin 2147.55
Zydus Lifesciences 973.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.